2012-05-01
Self-reported cognitive functioning in postmenopausal breast cancer patients before and during endocrine treatment: Findings from the neuropsychological TEAM side-study
Publication
Publication
Psycho-Oncology: journal of the psychological, social and behavioral dimensions of cancer , Volume 21 - Issue 5 p. 479- 487
Objective: This study aimed to evaluate self-reported cognitive functioning of postmenopausal breast cancer patients before and during endocrine treatment compared with healthy female controls, and to investigate associations between self-reported cognitive functioning, cognitive test performance and anxiety/depression, fatigue, and menopausal complaints. Methods: Self-reported cognitive functioning, anxiety/depression, fatigue, menopausal complaints, and cognitive tests performance were assessed before (T1) and after 1 year (T2) of adjuvant endocrine treatment in postmenopausal chemotherapy-naïve breast cancer patients. Self-reported cognitive functioning was assessed by the cognitive failures questionnaire and interview questions concerning cognitive complaints. Patients participated in the TEAM-trial, a prospective randomized study investigating tamoxifen versus exemestane as adjuvant therapy for hormone-sensitive breast cancer. Identical information was obtained from healthy postmenopausal volunteers. Results: Two measures for self-reported cognitive functioning provided the distinctive results. At T1 and T2, healthy controls reported a higher frequency of cognitive failures than patients; change over time did not differ between groups. The prevalence of cognitive complaints did not differ between the groups at T1, but change over time regarding attention/concentration complaints differed between groups, due to an increased prevalence in tamoxifen users. Self-reported cognitive functioning showed moderate associations with anxiety/depression, fatigue, and menopausal complaints. Cognitive test performance was not associated with self-reported cognitive functioning, but weakly with anxiety/depression and fatigue. Conclusion: Adjuvant therapy with tamoxifen and exemestane did not influence the self-reported frequency of cognitive failures. Increased attention/ concentration complaints were observed in tamoxifen users, but not in exemestane users. This latter finding should be confirmed with better validated instruments. Copyright
Additional Metadata | |
---|---|
, , , , , | |
doi.org/10.1002/pon.1928, hdl.handle.net/1765/91833 | |
Psycho-Oncology: journal of the psychological, social and behavioral dimensions of cancer | |
Organisation | Erasmus MC: University Medical Center Rotterdam |
Schilder, C., Seynaeve, C., Linn, S., Boogerd, W., Beex, L., Gundy, C., … Schagen, S. (2012). Self-reported cognitive functioning in postmenopausal breast cancer patients before and during endocrine treatment: Findings from the neuropsychological TEAM side-study. Psycho-Oncology: journal of the psychological, social and behavioral dimensions of cancer (Vol. 21, pp. 479–487). doi:10.1002/pon.1928 |